Pure Global AI
NCT06363851Not yet recruiting

Single-ascending Dose Study of Kylo-11 in Healthy Subjects

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-11 in Healthy Subjects
Kylonova (Xiamen) Biopharma co., LTD.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Cardiovascular Diseases
Drug/Device/Intervention
Kylo-11
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Kylonova (Xiamen) Biopharma co., LTD.
Location
Chengdu, China
Timeline & enrollment
Phase
Phase 1
Start date
May 31, 2024
End date
Nov 30, 2025
Enrollment
60 participants
Primary outcome

Incidence of adverse events

Summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose
 study in healthy volunteers. Kylo-11 will be evaluated in approximately 60 subjects to assess
 safety, tolerability, pharmacokinetics and pharmacodynamic effects.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseOther ill-defined heart diseasesHeart disease, unspecifiedObservation for other suspected cardiovascular diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06363851
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06363851 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kylonova (Xiamen) Biopharma co., LTD. and is currently Not yet recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.